A variety of PI3K/AKT inhibitors are currently under investigation in prostate cancer in combination with other therapies such as ARSIs, docetaxel, bicalutamide, and hydroxychloroquine (NCT06190899, NCT03218826, NCT05348577, NCT01480154, NCT04586270, NCT01251861). The gene discussed is PIK3CA; the disease is prostate cancer.